---
title: 'Feasibility of targeted therapies in the adjuvant setting of early breast
  cancer in men: real-world data from a population-based registry'
date: '2024-03-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38472501/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240313180711&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: In a large real-world sample, more men with eBC are at clinical
  high risk according to the inclusion criteria of monarchE, NATALEE and OlympiA than
  would be expected in women. This is most likely due to more advanced stages at initial
  diagnosis in men. To evaluate whether CDK4/6 and PARP inhibitors improve prognosis
  also in men should be the topic of future real- world ...'
disable_comments: true
---
CONCLUSION: In a large real-world sample, more men with eBC are at clinical high risk according to the inclusion criteria of monarchE, NATALEE and OlympiA than would be expected in women. This is most likely due to more advanced stages at initial diagnosis in men. To evaluate whether CDK4/6 and PARP inhibitors improve prognosis also in men should be the topic of future real- world ...